Drug profile · INN
bacitracin zinc
NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE
bacitracin zinc (NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE) is a c55-isoprenyl pyrophosphate inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — bacitracin zinc
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 4
- Data quality
- 0.84
Quick answer
bacitracin zinc (NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE) is a c55-isoprenyl pyrophosphate inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
C55-isoprenyl pyrophosphate inhibitor
Primary target: C55-isoprenyl pyrophosphate
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Congress & event coverage
- PresentationESMO Gastrointestinal Cancers Congress
- PresentationPharma Manufacturing World
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is bacitracin zinc?
bacitracin zinc (NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE) is a c55-isoprenyl pyrophosphate inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for bacitracin zinc?
NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE is a marketed brand name for bacitracin zinc. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of bacitracin zinc?
bacitracin zinc has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.